Alector Inc
alector.comAlector Inc (NASDAQ: ALEC) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It generates no product revenue, operating instead on collaboration and funding arrangements with partners such as GSK. Its lead clinical asset, nivisnebart (formerly AL101/GSK4527226), is a monoclonal antibody designed to elevate progranulin (PGRN) levels in the brain, co-developed with GSK for early Alzheimer's disease and potentially Parkinson's disease. Wholly owned preclinical programs include AL137, a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease; AL050, a GCase enzyme replacement therapy for Parkinson's disease and Lewy body dementia; and brain-penetrant siRNA programs targeting tau, alpha-synuclein, and NLRP3. Alector's platform combines antibody-brain carrier (ABC) technology, iPSC-based assays, biomarker-driven patient selection, and genetics-validated target identification. As of the 10-K filed February 25, 2026, all programs remain in clinical or preclinical development with no approved products.
Products & Services
Nivisnebart (AL101/GSK4527226): clinical-stage anti-PGRN monoclonal antibody for Alzheimer's disease and Parkinson's disease, co-developed with GSK. AL137: preclinical brain-penetrant anti-amyloid beta antibody for Alzheimer's disease. AL050: preclinical GCase enzyme replacement therapy for Parkinson's disease and Lewy body dementia. Brain-penetrant siRNA programs targeting tau (Alzheimer's disease), alpha-synuclein (Parkinson's disease), and NLRP3 (multiple neurodegenerative conditions). Proprietary antibody-brain carrier (ABC) technology platform.
Revenue Model
Collaboration revenue from partnership arrangements, primarily with GSK for co-development of nivisnebart. No product revenue as of the 10-K filed February 25, 2026.
Customers & Markets
Patients with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia, and neuronal ceroid lipofuscinosis. Collaboration partner: GSK.
Geographic Exposure
Headquartered in the United States. Clinical and commercial planning references the United States and European Union as target markets per the 10-K filed February 25, 2026.
Financial Snapshot
Loading...
